<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kurskvest</journal-id><journal-title-group><journal-title xml:lang="ru">Человек и его здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Humans and their health</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1998-5746</issn><issn pub-type="epub">1998-5754</issn><publisher><publisher-name>Kursk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21626/vestnik/2025-2/05</article-id><article-id custom-type="edn" pub-id-type="custom">JSEFEW</article-id><article-id custom-type="elpub" pub-id-type="custom">kurskvest-1416</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MEDICOBIOLOGICAL SCIENCES</subject></subj-group></article-categories><title-group><article-title>Оценка антибиотикорезистентности и антибиотикочувствительности инфекционных агентов у пациентов многопрофильного соматического стационара после пандемии COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Assessment of antibiotic resistance and antibiotic sensitivity of infectious agents in patients of a multidisciplinary somatic hospital after the COVID-19 pandemic</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5904-2828</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаврилюк</surname><given-names>Евгения Викторовна</given-names></name><name name-style="western" xml:lang="en"><surname>Gavriliuk</surname><given-names>Evgeniia V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, доцент, зав. кафедрой внутренних болезней Института непрерывного образования, КГМУ, г. Курск</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Associate Professor, Head of the Department of Internal Diseases of the Institute of Continuing Education, KSMU, Kursk, Russian Federation</p></bio><email xlink:type="simple">ganneta@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-5841-6811</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Байрамова</surname><given-names>Лия Шамсаддиновна</given-names></name><name name-style="western" xml:lang="en"><surname>Bayramova</surname><given-names>Liya S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-клинический фармаколог отдела организации лекарственного обеспечения, КОМКБ, г. Курск</p></bio><bio xml:lang="en"><p>Clinical pharmacologist of the Department of Organization of drug supply, KRMCH, Kursk, Russian Federation</p></bio><email xlink:type="simple">a_vrora89@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6788-518X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прибылова</surname><given-names>Надежда Николаевна</given-names></name><name name-style="western" xml:lang="en"><surname>Pribylova</surname><given-names>Nadezhda N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, профессор кафедры внутренних болезней Института непрерывного образования, КГМУ, г. Курск</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Professor of the Department of Internal Diseases of the Institute of Continuing Education, KSMU, Kursk, Russian Federation</p></bio><email xlink:type="simple">pribylova_nadezda@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Курский государственный медицинский университет (КГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kursk State Medical University (KSMU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Курская областная многопрофильная клиническая больница (КОМКБ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kursk Regional Multidisciplinary Clinical Hospital (KRMCH)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>07</day><month>07</month><year>2025</year></pub-date><volume>28</volume><issue>2</issue><fpage>37</fpage><lpage>44</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гаврилюк Е.В., Байрамова Л.Ш., Прибылова Н.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Гаврилюк Е.В., Байрамова Л.Ш., Прибылова Н.Н.</copyright-holder><copyright-holder xml:lang="en">Gavriliuk E.V., Bayramova L.S., Pribylova N.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.kursk-vestnik.ru/jour/article/view/1416">https://www.kursk-vestnik.ru/jour/article/view/1416</self-uri><abstract><p>Цель - определить микробный пейзаж и провести оценку чувствительности и резистентности выделенных микроорганизмов к антибактериальным препаратам у пациентов многопрофильного соматического стационара.</p><sec><title>Материалы и методы</title><p>Материалы и методы. В работе представлены результаты 1203 посевов биологического материала (бронхиального аспирата, мокроты, плевральной жидкости и смывов с бронхов) у пациентов соматических отделений ОБУЗ «Курская областная многопрофильная клиническая больница» за 2022-2023 гг., а также результаты исследования посевов на антибиотикочувствительность и антибиотикорезистентность к антимикробным препаратам.</p></sec><sec><title>Результаты</title><p>Результаты. Наибольшее количество положительных результатов микробиологического исследования было получено в мокроте (88,0%) и бронхиальном аспирате (80,1%), тогда как в плевральной жидкости и бронхиальных смывах положительных результатов было значительно меньше - 42,6% и 47,8%, соответственно. Лидирующие представители в биологических материалах пациентов соматических отделений занимали Streptococcus pyogenes (18%), Klebsiella pneumoniae (15,6%), Acinetobacter baumannii (14,9%), Pseudomonas aeruginosa (11,1%), Candida albicans (6,7%), в то время как золотистый стафилококк наблюдался только в 4,2% образцов. Streptococcus pyogenes , выявленный у пациентов соматических отделений, был чувствителен к хлорамфениколу в 90% и клиндамицину в 89% и устойчив к эритромицину в 53% и азитромицину в 45%, в то время как в 71% случаев была отмечена промежуточная, т.е. частичная, чувствительность (резистентность) к левофлоксацину.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные результаты позволяют лечащему врачу выбирать наиболее эффективные и согласованные с утвержденными клиническими рекомендациями схемы для эмпирической антимикробной фармакотерапии у пациентов соматических отделений многопрофильного стационара.</p></sec></abstract><trans-abstract xml:lang="en"><p>Objective - to determine the microbial landscape and evaluate the sensitivity and resistance of isolated microorganisms to antibacterial drugs in patients of a multidisciplinary somatic hospital.</p><sec><title>Materials and methods</title><p>Materials and methods. The paper presents the results of 1203 crops of biological material (bronchial aspirate, sputum, pleural fluid and bronchial flushes) in patients of the somatic departments of the Kursk Regional Multidisciplinary Clinical Hospital for 2022-2023, as well as the results of a study of crops for antibiotic sensitivity and antibiotic resistance to antimicrobials.</p></sec><sec><title>Results</title><p>Results. The largest number of positive microbiological examination results were obtained in sputum (88.0%) and bronchial aspirate (80.1%), while there were significantly fewer positive results in pleural fluid and bronchial flushes - 42.6% and 47.8%, respectively. The leading representatives in the biological materials of patients in somatic departments were Streptococcus pyogenes (18%), Klebsiella pneumoniae (15.6%), Acinetobacter baumannii (14.9%), Pseudomonas aeruginosa (11.1%), Candida albicans (6.7%), while Staphylococcus aureus was observed only in 4.2% of samples. Streptococcus pyogenes, detected in patients with somatic departments, was sensitive to chloramphenicol in 90% and clindamycin in 89% and resistant to erythromycin in 53% and azithromycin in 45%, while in 71% of cases intermediate, i.e. partial, sensitivity (resistance) to levofloxacin was noted.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results obtained allow the attending physician to choose the most effective and consistent with approved clinical recommendations regimens for empirical antimicrobial pharmacotherapy in patients with somatic departments of a multidisciplinary hospital.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>антибактериальная фармакотерапия</kwd><kwd>антибиотики</kwd><kwd>антибиотикочувствительность</kwd><kwd>антибиотикорезистентность</kwd><kwd>многопрофильный соматический стационар</kwd></kwd-group><kwd-group xml:lang="en"><kwd>antibacterial pharmacotherapy</kwd><kwd>antibiotics</kwd><kwd>antibiotic sensitivity</kwd><kwd>antibiotic resistance</kwd><kwd>multidisciplinary somatic hospital</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Карпин В.А., Шувалова О.И. Микробиом респираторной системы в современной пульмонологии. Флагман науки. 2024;5(16):186-189. DOI: 10.37539/2949-1991.2024.5.16.012. EDN: GXLGIM.</mixed-citation><mixed-citation xml:lang="en">Karpin V.A., Shuvalova O.I. Microbiome of the respiratory system in modern pulmonology. Flagship of science. 2024;5(16):186-189 (in Russ.). DOI: 10.37539/2949-1991.2024.5.16.012. EDN: GXLGIM.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lipinksi J.H., Ranjan P., Dickson R.P., O’Dwyer D.N. The Lung Microbiome. J Immunol. 2024;212(8): 1269-1275. DOI: 10.4049/jimmunol.2300716.</mixed-citation><mixed-citation xml:lang="en">Lipinksi J.H., Ranjan P., Dickson R.P., O’Dwyer D.N. The Lung Microbiome. J Immunol. 2024;212(8): 1269-1275. DOI: 10.4049/jimmunol.2300716.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sulaiman I., Wu B.G., Li Y., Tsay J.C., Sauthoff M., Scott A.S., Ji K., Koralov S.B., yet al. Functional lower airways genomic profiling of the microbiome to capture active microbial metabolism. Eur Respir J. 2021;58(1):2003434. DOI: 10.1183/13993003.03434-2020.</mixed-citation><mixed-citation xml:lang="en">Sulaiman I., Wu B.G., Li Y., Tsay J.C., Sauthoff M., Scott A.S., Ji K., Koralov S.B., yet al. Functional lower airways genomic profiling of the microbiome to capture active microbial metabolism. Eur Respir J. 2021;58(1):2003434. DOI: 10.1183/13993003.03434-2020.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Natalini J.G., Singh S., Segal L.N. The dynamic lung microbiome in health and disease. Nat Rev Microbiol. 2023;21:222-235. DOI: 10.1038/s41579-022-00821-x.</mixed-citation><mixed-citation xml:lang="en">Natalini J.G., Singh S., Segal L.N. The dynamic lung microbiome in health and disease. Nat Rev Microbiol. 2023;21:222-235. DOI: 10.1038/s41579-022-00821-x.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Natalini J.G., Segal L.N. Lung microbial-host interface through the lens of multi-omics. Mucosal Immunol. 2022;15(5):837-845. DOI: 10.1038/s41385-022-00541-8.</mixed-citation><mixed-citation xml:lang="en">Singh S., Natalini J.G., Segal L.N. Lung microbial-host interface through the lens of multi-omics. Mucosal Immunol. 2022;15(5):837-845. DOI: 10.1038/s41385-022-00541-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Мирзаханов С.М., Мирзаханов А.М. Анализ антибиотикочувствительности и антибиотикорезистентности возбудителей Streptococcus pneumo-niae, Staphioloccus aureus, Streptococcus haemolyticus у детей в отделении пульмонологии. Современные проблемы науки и образования. 2022;(1):70. DOI: 10.17513/spno.31454. EDN: XCVCPY.</mixed-citation><mixed-citation xml:lang="en">Mirzakhanov S.M., Mirzakhanov A.M. Analysis of antibiotic sensitivity and antibiotic resistance of Streptococcus pneumoniae, Staphilococcus aureus, Streptococcus haemolyticus pathogens in children in the Department of Pulmonology. Modern problems of science and education. 2022;(1):70 (in Russ.). DOI: 10.17513/spno.31454. EDN: XCVCPY.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Белобородов В.Б., Гусаров В.Г., Дехнич А.В., Замятин М.Н., Зубарева Н.А., Зырянов С.К., Камышова Д.А., Климко Н.Н. и др. Диагностика и антимикробная терапия инфекций, вызванных полирезистентными микроорганизмами. Методические рекомендации Российской некоммерческой общественной организации «Ассоциация анестезиологов-реаниматологов», Межрегиональной общественной организации «Альянс клинических химиотерапевтов и микробиологов», Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии (МАКМАХ), общественной организации «Российский Сепсис Форум». Вестник анестезиологии и реаниматологии. 2020;17(1): 52-83. DOI: 10.21292/2078-5658-2020-17-1-52-83. EDN: URHOQO.</mixed-citation><mixed-citation xml:lang="en">Beloborodov V.B., Gusarov V.G., Dekhnich A.V., Zamyatin M.N., Zubareva N.A., Zyryanov S.K., Kamyshova D.A., Klimko N.N., et al. Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms. Guidelines of the Association of Anesthesiologists-Intensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum. Messenger of Anesthesiology and Resuscitation. 2020;17(1):52-83 (in Russ.). DOI: 10.21292/2078-5658-2020-17-1-52-83. EDN: URHOQO.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wu B.G., Sulaiman I., Tsay J.J., Perez L., Franca B., Li Y., Wang J., Gonzalez A.N., et al. Episodic aspiration with oral commensals induces a MyD88-dependent, pulmonary T-helper cell type 17 response that mitigates susceptibility to Streptococcus pneumoniae. Am J Respir Crit Care Med. 2021;203(9): 1099-1111. DOI: 10.1164/rccm.202005-1596OC.</mixed-citation><mixed-citation xml:lang="en">Wu B.G., Sulaiman I., Tsay J.J., Perez L., Franca B., Li Y., Wang J., Gonzalez A.N., et al. Episodic aspiration with oral commensals induces a MyD88-dependent, pulmonary T-helper cell type 17 response that mitigates susceptibility to Streptococcus pneumoniae. Am J Respir Crit Care Med. 2021;203(9): 1099-1111. DOI: 10.1164/rccm.202005-1596OC.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Фесенко О.В., Синопальников А.И., Янина А.А., Токмулина Г.М. Рациональная антибактериальная терапия респираторных инфекций в реальной практике. Доктор.Ру. 2020;19(5):67-73. DOI: 10.31550/1727-2378-2020-19-5-67-73. EDN: QPOAIH.</mixed-citation><mixed-citation xml:lang="en">Fesenko O.V., Sinopal’nikov A.I., Yanina A.A., Tokmulina G.M. Sustainable Antibacterial Management of Respiratory Infections in Actual Practice. Doctor.Ru. 2020;19(5):67-73 (in Russ.). DOI: 10.31550/1727-2378-2020-19-5-67-73. EDN: QPOAIH.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Акимкин В.Г., Тутельян А.В., Шулакова Н.И., Воронин Е.М. Пандемия COVID-19: новый виток нарастания антибиотикорезистентности. Инфекционные болезни. 2021;19(3):133-138. DOI: 10.20953/1729-9225-2021-3-133-138. EDN: XTWDKK.</mixed-citation><mixed-citation xml:lang="en">Akimkin V.G., Tutelyan A.V., Shulakova N.I., Voronin E.M. COVID-19 pandemic: a new round of antibiotic resistance. Infectious diseases. 2021;19(3):133-138 (in Russ.). DOI: 10.20953/1729-9225-2021-3-133-138. EDN: XTWDKK.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Martin, C., Guzior, D.V., Gonzalez C.T., Okros M., Mielke J., Padillo L., Querido G., Gil M., et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy. Respir Res. 2023;24:317. DOI: 10.1186/s12931-023-02630-z.</mixed-citation><mixed-citation xml:lang="en">Martin, C., Guzior, D.V., Gonzalez C.T., Okros M., Mielke J., Padillo L., Querido G., Gil M., et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy. Respir Res. 2023;24:317. DOI: 10.1186/s12931-023-02630-z.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tunney M.M., Wark P. Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist. Eur Respir J. 2023;62(2):2301008. DOI: 10.1183/13993003.01008-2023.</mixed-citation><mixed-citation xml:lang="en">Tunney M.M., Wark P. Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist. Eur Respir J. 2023;62(2):2301008. DOI: 10.1183/13993003.01008-2023.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ampulembang D.T., Handayani I., Kadir N.A. Bacterial Identification and Antibiotic Sensitivity Tests of COVID-19 Patients at ICU Wahidin Sudirohusodo Hospital. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2025;31(2):155-160. DOI: 10.24293/ijcpml.v31i2.2275.</mixed-citation><mixed-citation xml:lang="en">Ampulembang D.T., Handayani I., Kadir N.A. Bacterial Identification and Antibiotic Sensitivity Tests of COVID-19 Patients at ICU Wahidin Sudirohusodo Hospital. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2025;31(2):155-160. DOI: 10.24293/ijcpml.v31i2.2275.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Российские рекомендации. Определение чувствительности микроорганизмов к антимикробным препаратам. Версия 2024-02. Год утверждения (частота пересмотра): 2024 (пересмотр ежегодно). Смоленск: МАКМАХ, СГМУ, 2024. 192 с.URL: https://www.antibiotic.ru/files/334/ocmap2024.pdf</mixed-citation><mixed-citation xml:lang="en">Russian recommendations. Determination of the sensitivity of microorganisms to antimicrobial drugs. Version 2024-02. Year of approval (frequency of revision): 2024 (annual revision). Smolensk: MAKMAKH, SSMU, 2024. 192 p. (in Russ.). URL: https://www.antibiotic.ru/files/334/ocmap2024.pdf</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bharadwaj A., Rastogi A., Pandey S., Gupta S., Sohal J.S. Multidrug-resistant bacteria: Their mechanism of action and prophylaxis. Biomed Res Int. 2022;2022:5419874. DOI: 10.1155/2022/5419874.</mixed-citation><mixed-citation xml:lang="en">Bharadwaj A., Rastogi A., Pandey S., Gupta S., Sohal J.S. Multidrug-resistant bacteria: Their mechanism of action and prophylaxis. Biomed Res Int. 2022;2022:5419874. DOI: 10.1155/2022/5419874.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации. Определение чувствительности микроорганизмов к антимикробным препаратам. Версия 2021-01. Год утверждения (частота пересмотра): 2021 (пересмотр ежегодно). 2021. 225 с. URL: https://www.antibiotic.ru/files/321/clrec-dsma2021.pdf</mixed-citation><mixed-citation xml:lang="en">Recommendations. Determination of the sensitivity of microorganisms to antimicrobial drugs. Version 2021-01. Year of approval (frequency of revision): 2021 (revision annually). 2021. 225 p. (in Russ.). URL: https://www.antibiotic.ru/files/321/clrec-dsma2021.pdf</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Nolley E.P., Sahetya S.K., Hochberg C.H., Hossen S., Hager D.N., Brower R.G., Stuart E.A., Checkley W. Outcomes among mechanically ventilated patients with severe pneumonia and acute hypoxemic respiratory failure from SARS-CoV-2 and other etiologies. JAMA Network Open. 2023;6(1):e2250401. DOI: 10.1001/jamanetworkopen.2022.50401.</mixed-citation><mixed-citation xml:lang="en">Nolley E.P., Sahetya S.K., Hochberg C.H., Hossen S., Hager D.N., Brower R.G., Stuart E.A., Checkley W. Outcomes among mechanically ventilated patients with severe pneumonia and acute hypoxemic respiratory failure from SARS-CoV-2 and other etiologies. JAMA Network Open. 2023;6(1):e2250401. DOI: 10.1001/jamanetworkopen.2022.50401.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Agyepong N., Fordjour F., Owusu-Ofori A. Multidrugresistant Acinetobacter baumannii in healthcare settings in Africa. Frontiers in Tropical Diseases. 2023;4:1-9. DOI: 10.3389/fitd.2023.1110125</mixed-citation><mixed-citation xml:lang="en">Agyepong N., Fordjour F., Owusu-Ofori A. Multidrugresistant Acinetobacter baumannii in healthcare settings in Africa. Frontiers in Tropical Diseases. 2023;4:1-9. DOI: 10.3389/fitd.2023.1110125</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
